Breaking News

Asterias Leases New R&D Facilities

By Kristin Brooks | January 3, 2014

Expands development and manufacturing for cell therapy product portfolio

Asterias Biotherapeutics, a subsidiary of BioTime, has entered a long-term lease for a research, development, and manufacturing facility in Fremont, CA for its cell therapy product development activities. The facility has approximately 44,000 sq.-ft. of existing office, lab and vivarium space. The eight-year lease begins October 1, 2014 and has two five-year extension options.

Asterias will use a $4.4 million tenant improvement allowance to construct a production facility designed to satisfy U.S. and European cGMP requirements for cell banks and the company’s drug product candidates. Construction of the manufacturing facility is expected to begin 2Q14.

Asterias began product development activities at its current Menlo Park, CA location in October of 2013 after the closing of an asset contribution agreement with Geron Corp. and BioTime, Inc., under which Asterias acquired Geron’s human embryonic stem cell assets and minority stakes in two of BioTime’s subsidiaries. The product development portfolio includes two programs for neural progenitors cells, currently in clinical development for spinal cord injury, and dendritic cells targeting telomerase, in clinical development for cancer. The company’s preclinical portfolio includes chondrocytes for osteoarthritis and degenerative disc disease, and cardiomyocytes for heart failure.

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.